Want to join the conversation?
$CELG CFO Peter said that the company's 4Q15 total net product sales grew 24%. Product sales growth for the quarter and the year remained volume driven. Peter also stated that 25% of fourth quarter sales were reinvested in R&D due to increased clinical trial activity for $CELG's high potential late-stage programs.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.